JC17 Rec'd PCT/PTO 20 SEP 2005

PRELIMINARY AMENDMENT
NS Entry of PCT/GB2004/001369

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

Claim 1. (Original) A method of treatment of a human or non-human animal subject to combat inflammation arising from a condition associated with pain or a condition not associated with pain, said method comprising administering to said subject an effective amount of a physiologically tolerable strontium compound.

Claim 2. (Original Currently Amended) A—The method as claimed in claim 1, wherein said strontium compound is administered to the surface of the skin.

Claim 3. (Original Currently Amended) A—The method as claimed in either of claims claim 1—and 2, wherein said inflammation is not associated with pain.

Claim 4. (Original Currently Amended) A—The method as claimed in any one of claims claim 1—to 3, wherein said inflammation is not associated with a sporting injury.

Claim 5. (Original Currently Amended) A The method as claimed in any one of claims claim 1—to 4, wherein said administration is not oral.

Claims 6-7. (Cancelled).

Claim 8. (Currently Amended) Use—The method as claimed in either of claims 6 and 7claim 1, wherein said medicament strontium compound is administered further contains with a skin penetration enhancing agent.

Claim 9. (Currently Amended) Use—The method as claimed in claim 8, wherein said skin penetration enhancing agent is dimethylsulphoxide.

PRELIMINARY AMENDMENT NS Entry of PCT/GB2004/001369

Claim 10. (Currently Amended) Use—The method as claimed in any one of claims 6 to 8claim 1, wherein of a said strontium compound is selected from the group consisting of strontium chloride, strontium acetate and strontium nitrate.

Claim 11. (Currently Amended) Use—The method as claimed in any one of claims 6 to 10claim 1, wherein said strontium compound is a strontium complex, e.g., with a chelating agent.

Claim 12. (Currently Amended) Use—The method as claimed in claim 11, wherein said chelating agent is present in at least 2% mol excess relative to strontium.

Claim 13. (Currently Amended) Use—The method as claimed in claim 12, wherein said chelating agent is present in an excess of at least 50% mol relative to strontium.

Claim 14. (Currently Amended) Use—The method as claimed in claim 1 any one of claims 6 to 13, wherein said inflammation is associated with acne vulgaris.

Claim 15. (Currently Amended) Use The method as claimed in any one of claims 6 to 13 claim 1, wherein said inflammation is associated with psoriasis.

Claim 16. (Currently Amended) Use—The method as claimed in any one of claims 6 to 13 claim 1, wherein said inflammation is associated with radiation therapy.

Claim 17. (Currently Amended) Use The method as claimed in any one of claims 6 to 13 claim 1, wherein said inflammation is associated with arthritis.

Claim 18. (New) The method as claimed in claim 2, wherein said inflammation is not associated with pain.